Key result
Pegylated liposomal doxorubicin combined with gemcitabine achieved an overall response rate of 52% (95% CI, 37-67%) and a median overall survival of 16.1 months in metastatic breast cancer.
Why the study?
Does pegylated liposomal doxorubicin in combination with gemcitabine improve response rates in patients with metastatic breast cancer?
Population
49 patients with metastatic breast cancer, measurable disease, no prior chemotherapy for metastatic disease…
Design
Cohort
Authors
Loading...
Supports activity of pegylated liposomal doxorubicin plus gemcitabine in metastatic breast cancer; leaves open comparative efficacy versus standards.
Does pegylated liposomal doxorubicin in combination with gemcitabine improve response rates in patients with metastatic breast cancer?
Pegylated liposomal doxorubicin combined with gemcitabine is an active and well-tolerated front-line therapeutic option for metastatic breast cancer, yielding a 52% overall response rate.
Rivera et al. (2003) studied Metastatic breast cancer (n=49). Pegylated liposomal doxorubicin in combination with gemcitabine was evaluated on overall response rate (95% CI 37-67). Pegylated liposomal doxorubicin combined with gemcitabine achieved an overall response rate of 52% (95% CI, 37-67%) and a median overall survival of 16.1 months in metastatic breast cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: